BIOMOLECULAR RES INST LTD has a total of 87 patent applications. Its first patent ever was published in 1994. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and macromolecular chemistry and polymers are MOUNTAIN VIEW PHARMACEUTICALS, MOUNTAIN VIEW PHARMACEUTICALS INC and SHANGHAI FUDAN ZHANGJIANG BIO.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 42 | |
#2 | WIPO (World Intellectual Property Organization) | 10 | |
#3 | Canada | 9 | |
#4 | United States | 7 | |
#5 | EPO (European Patent Office) | 6 | |
#6 | New Zealand | 4 | |
#7 | Brazil | 3 | |
#8 | China | 3 | |
#9 | Japan | 1 | |
#10 | Mexico | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Macromolecular chemistry and polymers | |
#4 | Machines | |
#5 | Foods and drinks | |
#6 | Micro-structure and nano-technology | |
#7 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Special macromolecular compounds | |
#4 | Microorganisms | |
#5 | Peptides | |
#6 | Unspecified technologies | |
#7 | Nanostructure applications | |
#8 | Analysing materials | |
#9 | Enzymes | |
#10 | Fodder |
# | Name | Total Patents |
---|---|---|
#1 | Matthews Barry Ross | 22 |
#2 | Holan George | 21 |
#3 | Macreadie Ian | 10 |
#4 | Arunagiri Chinniah | 9 |
#5 | Garrett Thomas Peter John | 7 |
#6 | Gorman Jeffrey John | 6 |
#7 | Varghese Joseph Noozhumurry | 6 |
#8 | Chen Lin | 6 |
#9 | Fincher Geoffrey Bruce | 6 |
#10 | Mcphee Dale Alan | 5 |
Publication | Filing date | Title |
---|---|---|
AUPS110302A0 | Novel chalcone derivatives and uses thereof | |
AUPR520201A0 | Antiviral compounds | |
AUPR380501A0 | Improved molecule characterizing method and apparatus | |
AUPR276301A0 | Therapeutic ion channel blocking agents and methods of use thereof | |
AUPR202400A0 | Method of screening for inhibitors of alzheimer's disease | |
AUPQ888900A0 | Antiviral agents | |
AUPQ790300A0 | Diagnosis, prophylaxis and treatment of hepatitis C | |
AUPQ330099A0 | Inhibitors of interaction between the HIV-1 nef protein and the tumour suppressor P53 | |
AUPQ180499A0 | Beta-amyloid peptide inhibitors | |
AU4024599A | Method of designing agonists and antagonists to EGF receptor family | |
AUPP701098A0 | Beta-amyloid peptide inhibitors | |
AUPP449898A0 | Anti-viral compound | |
AUPP380498A0 | Egf receptor agonists and antagonists | |
AU4370897A | Cytotoxic peptides | |
AUPO768597A0 | Anti-paramyxoviridae compounds | |
AUPO770297A0 | Anti-viral compound | |
AUPO268096A0 | Cytotoxic peptides | |
AUPO265996A0 | Cytotoxic peptides | |
AUPO104396A0 | Antiviral linear polymers | |
AUPO104496A0 | Angiogenic inhibitory compounds |